 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
| How to use this System |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
Kidney Cancer (clear cell carcinoma)
Kidney cancer forms in the tissues of the kidneys. Metastatic kidney cancer is cancer that has spread from the kidney to other organs in the body. More specifically, clear cell carcinoma is rare type of tumor, usually of the female genital tract, in which the inside of the cells look clear when viewed under a microscope. It is also referred to as clear cell adenocarcinoma and mesonephroma.
[Source: www.cancer.gov]
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Kidney Cancer Disease Study CRAD001L2201
The purpose of this clinical research study is to determine the effectiveness of an investigational drug combined with that of an additional drug for participants 18 years of age and older who have metastatic clear cell carcinoma of the kidney (Kidney Cancer). An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 2 Participation Duration: Participants will be required to visit their study site every two weeks for approximately two years. One group will be required to inject themselves three times a week and return to the study site every two weeks for an additional infusion treatment. Another group, will be required to take two tablets every day and return to the site every two weeks for an additional infusion treatment. Protocol Number: CRAD001L2201 |
